Theravance Biopharma (NASDAQ:TBPH) Given New $15.00 Price Target at HC Wainwright

Theravance Biopharma (NASDAQ:TBPH) had its target price lowered by HC Wainwright from $20.00 to $15.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently commented on TBPH. TD Cowen cut their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a hold rating for the company in a research report on Tuesday. SVB Leerink cut Theravance Biopharma from an outperform rating to a market perform rating and reduced their price objective for the company from $15.00 to $10.00 in a research report on Tuesday. BTIG Research assumed coverage on Theravance Biopharma in a research report on Friday, April 12th. They issued a buy rating and a $21.00 target price on the stock. Finally, StockNews.com lowered shares of Theravance Biopharma from a buy rating to a hold rating in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $13.75.

Theravance Biopharma Trading Down 0.3 %

TBPH stock traded down $0.02 during midday trading on Tuesday, hitting $7.66. The company’s stock had a trading volume of 316,595 shares, compared to its average volume of 410,832. The company has a market cap of $372.51 million, a PE ratio of -8.91 and a beta of 0.24. The firm’s 50-day moving average is $9.01 and its 200-day moving average is $9.05. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The business had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 20.63%. During the same period last year, the business earned ($0.28) earnings per share. Analysts expect that Theravance Biopharma will post -0.42 earnings per share for the current year.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares of the company’s stock, valued at $3,023,685. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The disclosure for this sale can be found here. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. grew its position in shares of Theravance Biopharma by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,824 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Theravance Biopharma by 31.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,330 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 2,227 shares in the last quarter. Gerber LLC purchased a new stake in shares of Theravance Biopharma during the 4th quarter valued at $112,000. Simplicity Solutions LLC acquired a new stake in shares of Theravance Biopharma in the 4th quarter worth $141,000. Finally, Bleakley Financial Group LLC purchased a new position in Theravance Biopharma during the 4th quarter worth $141,000. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.